Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells.

Tawfik D, Groth C, Gundlach JP, Peipp M, Kabelitz D, Becker T, Oberg HH, Trauzold A, Wesch D.

Front Immunol. 2019 Aug 28;10:2044. doi: 10.3389/fimmu.2019.02044. eCollection 2019.

2.

Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells.

Oberg HH, Wesch D, Kalyan S, Kabelitz D.

Front Immunol. 2019 Jul 18;10:1690. doi: 10.3389/fimmu.2019.01690. eCollection 2019.

3.

Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling.

Flynn CM, Garbers Y, Lokau J, Wesch D, Schulte DM, Laudes M, Lieb W, Aparicio-Siegmund S, Garbers C.

Sci Rep. 2019 May 13;9(1):7306. doi: 10.1038/s41598-019-43617-5.

4.

POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma.

Rahn S, Krüger S, Mennrich R, Goebel L, Wesch D, Oberg HH, Vogel I, Ebsen M, Röcken C, Helm O, Sebens S.

Oncotarget. 2019 Feb 22;10(16):1572-1588. doi: 10.18632/oncotarget.26705. eCollection 2019 Feb 22.

5.

TGF-β enhances the cytotoxic activity of Vδ2 T cells.

Peters C, Meyer A, Kouakanou L, Feder J, Schricker T, Lettau M, Janssen O, Wesch D, Kabelitz D.

Oncoimmunology. 2018 Sep 26;8(1):e1522471. doi: 10.1080/2162402X.2018.1522471. eCollection 2019.

6.

The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness.

Melandri D, Zlatareva I, Chaleil RAG, Dart RJ, Chancellor A, Nussbaumer O, Polyakova O, Roberts NA, Wesch D, Kabelitz D, Irving PM, John S, Mansour S, Bates PA, Vantourout P, Hayday AC.

Nat Immunol. 2018 Dec;19(12):1352-1365. doi: 10.1038/s41590-018-0253-5. Epub 2018 Nov 12.

PMID:
30420626
7.

DNA methylation profiling of hepatosplenic T-cell lymphoma.

Bergmann AK, Fataccioli V, Castellano G, Martin-Garcia N, Pelletier L, Ammerpohl O, Bergmann J, Bhat J, Pau ECS, Martín-Subero JI, Moffitt AB, Valencia A, Oberg HH, Wesch D, Jayne S, Dyer MJS, Kabelitz D, Gaulard P, Siebert R.

Haematologica. 2019 Mar;104(3):e104-e107. doi: 10.3324/haematol.2018.196196. Epub 2018 Oct 18. No abstract available.

8.

Anti-CD3 Fab Fragments Enhance Tumor Killing by Human γδ T Cells Independent of Nck Recruitment to the γδ T Cell Antigen Receptor.

Juraske C, Wipa P, Morath A, Hidalgo JV, Hartl FA, Raute K, Oberg HH, Wesch D, Fisch P, Minguet S, Pongcharoen S, Schamel WW.

Front Immunol. 2018 Jul 9;9:1579. doi: 10.3389/fimmu.2018.01579. eCollection 2018.

9.

Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.

Oberg HH, Kellner C, Gonnermann D, Sebens S, Bauerschlag D, Gramatzki M, Kabelitz D, Peipp M, Wesch D.

Front Immunol. 2018 Apr 19;9:814. doi: 10.3389/fimmu.2018.00814. eCollection 2018.

10.

ADAM17 inhibition enhances platinum efficiency in ovarian cancer.

Hedemann N, Rogmans C, Sebens S, Wesch D, Reichert M, Schmidt-Arras D, Oberg HH, Pecks U, van Mackelenbergh M, Weimer J, Arnold N, Maass N, Bauerschlag DO.

Oncotarget. 2018 Mar 23;9(22):16043-16058. doi: 10.18632/oncotarget.24682. eCollection 2018 Mar 23.

11.

Regulatory functions of γδ T cells.

Peters C, Kabelitz D, Wesch D.

Cell Mol Life Sci. 2018 Jun;75(12):2125-2135. doi: 10.1007/s00018-018-2788-x. Epub 2018 Mar 8. Review.

PMID:
29520421
12.

Influence of physical activity on the immune system in breast cancer patients during chemotherapy.

Schmidt T, Jonat W, Wesch D, Oberg HH, Adam-Klages S, Keller L, Röcken C, Mundhenke C.

J Cancer Res Clin Oncol. 2018 Mar;144(3):579-586. doi: 10.1007/s00432-017-2573-5. Epub 2018 Jan 5.

PMID:
29305709
13.

MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells.

Kaehler M, Ruemenapp J, Gonnermann D, Nagel I, Bruhn O, Haenisch S, Ammerpohl O, Wesch D, Cascorbi I, Bruckmueller H.

Oncotarget. 2017 Sep 26;8(54):92018-92031. doi: 10.18632/oncotarget.21272. eCollection 2017 Nov 3.

14.

In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.

Chitadze G, Flüh C, Quabius ES, Freitag-Wolf S, Peters C, Lettau M, Bhat J, Wesch D, Oberg HH, Luecke S, Janssen O, Synowitz M, Held-Feindt J, Kabelitz D.

Oncoimmunology. 2017 Aug 8;6(11):e1358839. doi: 10.1080/2162402X.2017.1358839. eCollection 2017.

15.

Physical activity influences the immune system of breast cancer patients.

Schmidt T, van Mackelenbergh M, Wesch D, Mundhenke C.

J Cancer Res Ther. 2017 Jul-Sep;13(3):392-398. doi: 10.4103/0973-1482.150356. Review.

16.

The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity.

Chitadze G, Oberg HH, Wesch D, Kabelitz D.

Trends Immunol. 2017 Sep;38(9):668-678. doi: 10.1016/j.it.2017.06.004. Epub 2017 Jul 11. Review.

PMID:
28709825
17.

CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.

Peipp M, Wesch D, Oberg HH, Lutz S, Muskulus A, van de Winkel JGJ, Parren PWHI, Burger R, Humpe A, Kabelitz D, Gramatzki M, Kellner C.

Scand J Immunol. 2017 Oct;86(4):196-206. doi: 10.1111/sji.12581.

18.

Human Vδ2 T cells are a major source of interleukin-9.

Peters C, Häsler R, Wesch D, Kabelitz D.

Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12520-12525. Epub 2016 Oct 17.

19.

Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.

Oberg HH, Grage-Griebenow E, Adam-Klages S, Jerg E, Peipp M, Kellner C, Petrick D, Gonnermann D, Freitag-Wolf S, Röcken C, Sebens T, Vogel I, Becker T, Ebsen M, Kabelitz D, Wesch D, Sebens S.

Pancreatology. 2016 Nov - Dec;16(6):1069-1079. doi: 10.1016/j.pan.2016.07.008. Epub 2016 Jul 11.

PMID:
27424476
20.

NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors.

Chitadze G, Lettau M, Luecke S, Wang T, Janssen O, Fürst D, Mytilineos J, Wesch D, Oberg HH, Held-Feindt J, Kabelitz D.

Oncoimmunology. 2015 Dec 10;5(4):e1093276. eCollection 2016 Apr.

21.

CD4+ T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4+ T cells in pancreatic cancer development.

Goebel L, Grage-Griebenow E, Gorys A, Helm O, Genrich G, Lenk L, Wesch D, Ungefroren H, Freitag-Wolf S, Sipos B, Röcken C, Schäfer H, Sebens S.

Oncoimmunology. 2015 Jan 22;4(4):e1000083. eCollection 2015 Apr.

22.

γδ T cell activation by bispecific antibodies.

Oberg HH, Kellner C, Gonnermann D, Peipp M, Peters C, Sebens S, Kabelitz D, Wesch D.

Cell Immunol. 2015 Jul;296(1):41-9. doi: 10.1016/j.cellimm.2015.04.009. Epub 2015 May 1.

PMID:
25979810
23.

Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.

Gonnermann D, Oberg HH, Kellner C, Peipp M, Sebens S, Kabelitz D, Wesch D.

Oncoimmunology. 2015 Jan 7;4(3):e988460. eCollection 2015 Mar.

24.

Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy.

Oberg HH, Kellner C, Peipp M, Sebens S, Adam-Klages S, Gramatzki M, Kabelitz D, Wesch D.

Front Immunol. 2014 Dec 17;5:643. doi: 10.3389/fimmu.2014.00643. eCollection 2014. Review.

25.

Human gamma delta T regulatory cells in cancer: fact or fiction?

Wesch D, Peters C, Siegers GM.

Front Immunol. 2014 Nov 20;5:598. doi: 10.3389/fimmu.2014.00598. eCollection 2014. Review.

26.

Inhibition of human γδ T cell proliferation and effector functions by neutrophil serine proteases.

Fazio J, Kalyan S, Wesch D, Kabelitz D.

Scand J Immunol. 2014 Dec;80(6):381-9. doi: 10.1111/sji.12221.

27.

The CD3 conformational change in the γδ T cell receptor is not triggered by antigens but can be enforced to enhance tumor killing.

Dopfer EP, Hartl FA, Oberg HH, Siegers GM, Yousefi OS, Kock S, Fiala GJ, Garcillán B, Sandstrom A, Alarcón B, Regueiro JR, Kabelitz D, Adams EJ, Minguet S, Wesch D, Fisch P, Schamel WWA.

Cell Rep. 2014 Jun 12;7(5):1704-1715. doi: 10.1016/j.celrep.2014.04.049. Epub 2014 May 22.

28.

Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.

Helm O, Mennrich R, Petrick D, Goebel L, Freitag-Wolf S, Röder C, Kalthoff H, Röcken C, Sipos B, Kabelitz D, Schäfer H, Oberg HH, Wesch D, Sebens S.

PLoS One. 2014 May 5;9(5):e94357. doi: 10.1371/journal.pone.0094357. eCollection 2014.

29.

L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression.

Grage-Griebenow E, Jerg E, Gorys A, Wicklein D, Wesch D, Freitag-Wolf S, Goebel L, Vogel I, Becker T, Ebsen M, Röcken C, Altevogt P, Schumacher U, Schäfer H, Sebens S.

Mol Oncol. 2014 Jul;8(5):982-97. doi: 10.1016/j.molonc.2014.03.001. Epub 2014 Apr 2.

30.

Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.

Oberg HH, Peipp M, Kellner C, Sebens S, Krause S, Petrick D, Adam-Klages S, Röcken C, Becker T, Vogel I, Weisner D, Freitag-Wolf S, Gramatzki M, Kabelitz D, Wesch D.

Cancer Res. 2014 Mar 1;74(5):1349-60. doi: 10.1158/0008-5472.CAN-13-0675. Epub 2014 Jan 21.

31.

18:1/18:1-Dioleoyl-phosphatidylglycerol prevents alveolar epithelial apoptosis and profibrotic stimulus in a neonatal piglet model of acute respiratory distress syndrome.

Preuß S, Scheiermann J, Stadelmann S, Omam FD, Winoto-Morbach S, Lex D, von Bismarck P, Adam-Klages S, Knerlich-Lukoschus F, Wesch D, Held-Feindt J, Uhlig S, Schütze S, Krause MF.

Pulm Pharmacol Ther. 2014 Jun;28(1):25-34. doi: 10.1016/j.pupt.2013.10.002. Epub 2013 Oct 16.

PMID:
24140177
32.

Phenotype and regulation of immunosuppressive Vδ2-expressing γδ T cells.

Peters C, Oberg HH, Kabelitz D, Wesch D.

Cell Mol Life Sci. 2014 May;71(10):1943-60. doi: 10.1007/s00018-013-1467-1. Epub 2013 Oct 4.

33.

Vδ2 T cell deficiency in granulomatosis with polyangiitis (Wegener's granulomatosis).

Fazio J, Quabius ES, Müller A, Adam-Klages S, Wesch D, Sebens S, Kalyan S, Lamprecht P, Kabelitz D.

Clin Immunol. 2013 Oct;149(1):65-72. doi: 10.1016/j.clim.2013.06.003. Epub 2013 Jun 18.

PMID:
23891739
34.

Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity.

Kabelitz D, Kalyan S, Oberg HH, Wesch D.

Oncoimmunology. 2013 Mar 1;2(3):e23304.

35.

Markers of operational immune tolerance after pediatric liver transplantation in patients under immunosuppression.

Schulz-Juergensen S, Marischen L, Wesch D, Oberg HH, Fändrich F, Kabelitz D, Burdelski M.

Pediatr Transplant. 2013 Jun;17(4):348-54. doi: 10.1111/petr.12079.

PMID:
23692599
36.

Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.

Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH, Kabelitz D.

Int J Cancer. 2013 Oct 1;133(7):1557-66. doi: 10.1002/ijc.28174. Epub 2013 Apr 18.

37.

Regulatory functions of γδ T cells.

Kabelitz D, Peters C, Wesch D, Oberg HH.

Int Immunopharmacol. 2013 Jul;16(3):382-7. doi: 10.1016/j.intimp.2013.01.022. Epub 2013 Feb 26. Review.

PMID:
23481270
38.

Topical application of phosphatidyl-inositol-3,5-bisphosphate for acute lung injury in neonatal swine.

Preuss S, Omam FD, Scheiermann J, Stadelmann S, Winoto-Morbach S, von Bismarck P, Adam-Klages S, Knerlich-Lukoschus F, Lex D, Wesch D, Held-Feindt J, Uhlig S, Schütze S, Krause MF.

J Cell Mol Med. 2012 Nov;16(11):2813-26. doi: 10.1111/j.1582-4934.2012.01618.x.

39.

poly(I:C) costimulation induces a stronger antiviral chemokine and granzyme B release in human CD4 T cells than CD28 costimulation.

Meyer T, Oberg HH, Peters C, Martens I, Adam-Klages S, Kabelitz D, Wesch D.

J Leukoc Biol. 2012 Oct;92(4):765-74. doi: 10.1189/jlb.0811407. Epub 2012 Jul 2.

PMID:
22750548
40.

Inositol-trisphosphate reduces alveolar apoptosis and pulmonary edema in neonatal lung injury.

Preuss S, Stadelmann S, Omam FD, Scheiermann J, Winoto-Morbach S, von Bismarck P, Knerlich-Lukoschus F, Lex D, Adam-Klages S, Wesch D, Held-Feindt J, Uhlig S, Schütze S, Krause MF.

Am J Respir Cell Mol Biol. 2012 Aug;47(2):158-69. doi: 10.1165/rcmb.2011-0262OC. Epub 2012 Mar 8.

PMID:
22403805
41.

Differential N termini in epithelial Na+ channel δ-subunit isoforms modulate channel trafficking to the membrane.

Wesch D, Althaus M, Miranda P, Cruz-Muros I, Fronius M, González-Hernández T, Clauss WG, Alvarez de la Rosa D, Giraldez T.

Am J Physiol Cell Physiol. 2012 Mar 15;302(6):C868-79. doi: 10.1152/ajpcell.00255.2011. Epub 2011 Dec 7.

42.
43.

Modulation of γδ T cell responses by TLR ligands.

Wesch D, Peters C, Oberg HH, Pietschmann K, Kabelitz D.

Cell Mol Life Sci. 2011 Jul;68(14):2357-70. doi: 10.1007/s00018-011-0699-1. Epub 2011 May 11. Review.

PMID:
21560072
44.

Functional expression of NOD2 in freshly isolated human peripheral blood γδ T cells.

Marischen L, Wesch D, Oberg HH, Rosenstiel P, Trad A, Shomali M, Grötzinger J, Janssen O, Tchikov V, Schütze S, Kabelitz D.

Scand J Immunol. 2011 Aug;74(2):126-34. doi: 10.1111/j.1365-3083.2011.02560.x.

45.

Regulation of T cell activation by TLR ligands.

Oberg HH, Juricke M, Kabelitz D, Wesch D.

Eur J Cell Biol. 2011 Jun-Jul;90(6-7):582-92. doi: 10.1016/j.ejcb.2010.11.012. Epub 2011 Feb 3. Review.

PMID:
21292344
46.

gammadelta T cells in cancer immunotherapy: current status and future prospects.

Chiplunkar S, Dhar S, Wesch D, Kabelitz D.

Immunotherapy. 2009 Jul;1(4):663-78. doi: 10.2217/imt.09.27. Review.

PMID:
20635991
47.

The neuronal-specific SGK1.1 kinase regulates {delta}-epithelial Na+ channel independently of PY motifs and couples it to phospholipase C signaling.

Wesch D, Miranda P, Afonso-Oramas D, Althaus M, Castro-Hernández J, Dominguez J, Morty RE, Clauss W, González-Hernández T, Alvarez de la Rosa D, Giraldez T.

Am J Physiol Cell Physiol. 2010 Oct;299(4):C779-90. doi: 10.1152/ajpcell.00184.2010. Epub 2010 Jul 14.

48.

gammadelta T-cells: basic features and potential role in vasculitis.

Kabelitz D, Fazio J, Adam-Klages S, Marget M, Oberg HH, Wesch D, Lamprecht P.

Clin Exp Rheumatol. 2010 Jan-Feb;28(1 Suppl 57):104-9. Review.

PMID:
20412714
49.

Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands.

Oberg HH, Ly TT, Ussat S, Meyer T, Kabelitz D, Wesch D.

J Immunol. 2010 May 1;184(9):4733-40. doi: 10.4049/jimmunol.0804279. Epub 2010 Apr 2.

50.

Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells.

Traxlmayr MW, Wesch D, Dohnal AM, Funovics P, Fischer MB, Kabelitz D, Felzmann T.

J Immunother. 2010 Jan;33(1):40-52. doi: 10.1097/CJI.0b013e3181b51447.

PMID:
19952957

Supplemental Content

Support Center